Key takeaway: Mold-Tek Packaging Limited held its Q4 FY26 Earnings Conference Call on May 11, 2026, where management reported improved capacity utilization across all units, particularly following the consolidation of five units into two in Hyderabad. The Chairman, J. Lakshmana Rao, highlighted a 37% growth in the Pharma packaging segment compared to Q4 of the previous year, contributing to an overall sales growth of 13.4% for the year. Management noted a double-digit growth in the paints business and a significant increase in the Food and FMCG segments, despite a decline in the Lubes segment due to the loss of a major client. The company set a goal of INR55 crores to INR60 crores in Pharma revenue for FY27, with plans for further product range expansion. Management also discussed ongoing capacity expansions and the impact of raw material price fluctuations on margins, indicating a focus on maintaining profitability.

Key takeaway: Mold-Tek Packaging Limited provided an investor presentation detailing its financial performance for the quarter and year ended March 31, 2026. The company reported a total revenue of INR 886.60 crore for FY26, reflecting a year-on-year growth of 13.48%. EBITDA increased by 20.72% to INR 173.66 crore, while PAT grew by 20.35% to INR 72.87 crore. The earnings per share (EPS) rose to 21.93 from 18.22 in the previous year. For Q4FY26, revenue reached INR 237.86 crore, a 17.40% increase from Q4FY25, with EBITDA growing by 23.09% to INR 48.10 crore and PAT increasing by 26.88% to INR 20.64 crore. The presentation highlighted the company's focus on innovation, sustainability, and capacity optimization, alongside a strong performance in the pharma and food segments.

Key takeaway: Mold-Tek Packaging Limited submitted an investor presentation for the quarter and nine months ended December 31, 2025. The presentation highlighted a total revenue of INR 648.75 crore for 9MFY26, marking a 12% increase from INR 578.71 crore in the previous year. EBITDA grew by 20% to INR 125.55 crore, while PAT increased by 18% to INR 52.23 crore. For Q3FY26, revenue was reported at INR 198.43 crore, a 4% rise from INR 190.68 crore in Q3FY25. EBITDA for the quarter was INR 38.67 crore, reflecting a 14% growth, and PAT was INR 14.35 crore, up 5% from the prior year. The company noted significant growth in its Pharma vertical, with a 190% increase in sales volume compared to Q3FY25. Additionally, a strategic MoU was signed with Vibe Generation Holdings for high-precision caps and closures, indicating a focus on high-margin, export-oriented growth.